Find Academic Supervisors

Professor Joy Ho is a Clinical Professor of Medicine at the University of Sydney’s Central Clinical School and a Senior Staff Specialist in Haematology at Royal Prince Alfred Hospital (RPAH). She serves as Director of Research and Head of the Multiple Myeloma Research Unit and Thalassemia/Haemoglobinopathy Unit at the Institute of Haematology, RPAH. Her research focuses on multiple myeloma, lymphoma, thalassemia, and iron metabolism, with a strong emphasis on clinical trials and translational medicine. She has led numerous multi-centre trials, including pioneering studies on CAR-T cell therapy for lymphoma and novel therapies for myeloma. Prof Ho’s education includes MB.BS. (Hons) from Sydney, D.Phil (Oxford), and fellowships from the Royal Australasian College of Physicians (RACP) and Royal College of Pathologists of Australasia (RCPA). She has held leadership roles in major hematology organizations, including the International Myeloma Working Group (IMWG) and the American Society of Hematology (ASH). Her international collaborations span Singapore, Thailand, and the United States. Her research interests include: Multiple Myeloma: Developing therapies targeting tumor microenvironment and immune modulation. Lymphoma: Pioneering CAR-T cell therapy in Australia. Thalassemia: Gene therapy and iron chelation advancements, including the landmark Northstar trial. Iron Metabolism: Investigating hepcidin and its role in transfusion-dependent anemias. Her recent publications highlight breakthroughs in CAR-T efficacy, myeloma biomarkers, and thalassemia management. Awards include the 2019 Sydney Local Health District Clinical Trial Award and election to the International Myeloma Society Board. She has secured over $2 million in grants for cutting-edge equipment and research. Prof Ho’s academic contributions extend to teaching and supervision, training fellows for RACP/RCPA certifications. Her leadership in national registries (e.g., Australian Haemoglobinopathy Registry) and guidelines (e.g., iron chelation protocols) underscores her commitment to advancing hematology care globally.

• Multiple Myeloma
• Lymphoma
• Thalassemia
• +5 more

Associate Professor Arnold Lining Ju is a biomedical engineer at the University of Sydney's School of Biomedical Engineering, affiliated with multiple institutes including the Heart Research Institute and Sydney Nano Institute. He holds academic positions in both the Faculty of Engineering and Faculty of Medicine & Health. Education: BSc from Peking University, PhD from Georgia Tech and Emory University (USA). Honors include Snow Fellowship, Heart Foundation Future Leader Fellowship, and multiple awards for cardiovascular research innovation. Research focuses on mechanobiology and biomechanics of thrombosis, developing microfluidic devices and organ-on-chip systems. Key projects include AI-driven single-cell nanotools, 3D biofabrication, and anti-thrombotic peptide design. Leads interdisciplinary teams and collaborates internationally with institutions like Harvard and University of Texas. Teaching roles include coordinating advanced cellular biomechanics courses and supervising PhD/Masters students in biomedical engineering and physiology. Over 50 peer-reviewed publications, with contributions to Nature Materials, Nature Communications, and other top journals.

• Mechanobiology
• Biomechanics
• Organ-on-chip
• +5 more

Dr. Yi David Ju is a Senior Research Fellow at RMIT University's School of Science and an ARC DECRA Fellow at La Trobe University's School of Cancer Medicine. He leads the Nanomedicine and Gene Therapeutics Laboratory at the Olivia Newton-John Cancer Research Institute (ONJCRI) and holds Honorary Fellowships at the University of Melbourne's Department of Microbiology & Immunology and Chemical Engineering. PhD from University of Melbourne (2017, Frank Caruso) 2017–2021 : Research Fellow at University of Melbourne 2021 : Vice-Chancellor’s Postdoctoral Fellow at RMIT 2023 : Visiting Researcher at University of Manchester's Nanomedicine Lab His research focuses on Bio-Nano Interactions , particularly Nanoparticle-Immune System dynamics, Lipid Nanoparticle Engineering for mRNA Delivery , and Poly(ethylene glycol) Alternatives . Key contributions include stealth nanoparticles for prolonged circulation, anti-PEG antibody dynamics in vaccine development, and patient-specific targeting models for chronic lymphocytic leukemia . Recent publications analyze hybrid immuno-PET-MRI probes for inflammation monitoring, zwitterionic PEG nanoparticles for reduced immunogenicity, and RAFT polymer-based LNPs for enhanced gene delivery . His work also explores supramolecular DNA-polyphenol assemblies and metal-phenolic coatings for controlled drug release . Scientific Awards ： 2023 ACIS ECR Lectureship Finalist, 2023 ACS Nano Impact Award 2022&2023 RMIT Enabling Capability Platform Funding 2021 CBNS Most Significant Publication Award 2020 CBNS Career Development Award 2019 Outstanding Postdoctoral Researcher Award 2019 Nanoscale Advances Oral Prize 2017 Reviewer Excellence Award for Chemistry of Materials 2014 Best Tutor Award Professional Roles ： Associate Editor, Journal of Materials Science Committee Member, Royal Australian Chemical Institute (Victorian Branch) Active Member, Australasian Colloid and Interface Society

• Nanotechnology
• mRNA Therapeutics
• Lipid Nanoparticle Formulation
• +4 more

Dr. Maru Castellanos Reynosa is a Senior Lecturer in Epidemiology & Communicable Disease Control at James Cook University (JCU), Australia. She holds a BSc in Chemical Biology (Universidad de San Carlos de Guatemala), a Master’s in Medical Microbiology (Liverpool School of Tropical Medicine), and a PhD in Epidemiology (University of Georgia). Her expertise spans infectious disease epidemiology, particularly tuberculosis, malaria, and HIV, with a focus on low-resource settings in Africa and Latin America. Research interests include: epidemiological study design, infectious disease transmission dynamics, and public health interventions. Her work emphasizes molecular epidemiology, co-infections, and climate impacts on pathogen spread. Key contributions include studies on TB social networks, HIV-TB co-infection outcomes, and malaria in pregnancy. Key Achievements: Recipient of the Schlumberger Faculty for the Future Program (2016) and Fulbright LASPAU Fellowship (2013) Teaching Excellence Award at JCU (2023) and Dissertation Completion Award (UGA, 2018) Over 35 peer-reviewed publications and 2 active research projects, including a capacity-building initiative for tropical disease control Professional Affiliations: Royal Society of Tropical Medicine & Hygiene, American Society of Tropical Medicine & Hygiene, and Organization for Women in Science for the Developing World (OWSD).

• Epidemiology
• Infectious Diseases
• Tuberculosis
• +5 more

Associate Professor Freda Passam is a Clinical Academic Haematologist at Royal Prince Alfred Hospital, University of Sydney, specializing in thrombosis and haemostasis. She leads the Haematology Research Group at the Charles Perkins Centre, focusing on platelet biology, endothelial cell dysfunction, and translational research in cardiovascular diseases. Her work integrates basic science with clinical applications, including developing microfluidic technologies like the Endo-chip for thrombosis diagnosis and therapy screening. Education: MD and PhD in Greece (angiogenesis in Hodgkin’s lymphoma), postdoctoral training at UNSW and Harvard University. Research spans platelet hyperactivity in diabetes, immune thrombosis (e.g., HIT), and thiol isomerase inhibitors as antithrombotics. Collaborates globally with institutions like Harvard and the University of Utah. Research Interests: 1) Platelet biomarkers in diabetes-related cardiovascular risk; 2) Immune thrombosis diagnostics/therapies (e.g., Endo-chip); 3) Bone marrow-on-chip models for thrombopoiesis. Current projects include SEC61B regulation of calcium flux, endothelial thromboinflammation, and ERp5/ERp57 roles in platelet production. Grants: Over $6M in funding from NHMRC, MRFF, NSW Health, and industry partnerships. Notable awards include Sydney Nano Grand Challenge Award (2022) and SLHD VTE Stewardship Award (2020). Advising: Mentors over 6 PhD/master’s students in thrombosis research, emphasizing clinical/research integration. Teaching includes Sydney Medicine curriculum, bedside tutorials, and student engagement in lab activities. Labs/Teams: Haematology Research Group (Charles Perkins Centre), collaborations with Sydney Health Partners, Harvard, and international haematology groups. Develops technologies like the Endo-chip and bone marrow-on-chip models.

• Thrombosis
• Cardiovascular diseases
• Endothelial cell biology
• +7 more

Professor Mark Polizzotto is Professor of Medicine in the College of Science and Medicine at the Australian National University (ANU), Group Leader in Cancer and Genome Science at the John Curtin School of Medical Research, and leads the Clinical Hub for Interventional Research (CHOIR). Previously, he served as a Senior Staff Haematologist at The Canberra Region Cancer Centre, Canberra Hospital. His research interests focus on the intersection of immunity, infection and cancer, with particular emphasis on developing new therapies to prevent and treat malignancy, especially infection-related cancers. His work spans Cancer Immunotherapy , Cancer Target Therapies , Infectious Disease Immunotherapy , HIV/HIV-related malignancies , and Global Oncology , with specific expertise in Human Herpesvirus-8 , Epstein Barr Virus , and Human Papillomavirus . His clinical specialties include Haematology , Infectious Diseases , and Tumour Immunology . His recent publications demonstrate a strong focus on clonal hematopoiesis in HIV patients, lymphoma outcomes in immunocompromised individuals, and therapeutic approaches for viral infections including SARS-CoV-2. His work frequently addresses the intersection of chronic viral infections and cancer development, with particular attention to global health applications. The Tony Ayers Award (2022) Professor Polizzotto has led multiple international clinical trials, including work on viral and HIV-associated cancers that has influenced global guidelines. He co-led the development of an oral immunomodulator for Kaposi sarcoma which led to the first new drug approval for KS in over 20 years. During the SARS-CoV-2 pandemic, he led international randomized trials of immunotherapies for COVID-19 at the invitation of the U.S. National Institutes of Health. He has a strong commitment to diversity and inclusion in clinical trials and to clinical research capacity development in resource-limited settings, having led trial capacity building efforts in West Africa and Indonesia for the U.S. National Institutes of Health.

• Cancer Immunotherapy
• Infectious Disease Immunotherapy
• HIV-Related Malignancies
• +6 more

Clinical Associate Professor Therese McGee is affiliated with the Westmead Clinical School, part of the Sydney Medical School at the University of Sydney. Her work focuses on maternal and neonatal health, particularly in obstetrics and gynaecology, with a strong emphasis on clinical research and guideline implementation. She investigates diverse topics such as perinatal outcomes, pandemic impacts on healthcare, and optimizing healthcare delivery models. Her research often addresses challenges in multiethnic populations and evaluates interventions to improve patient care and reduce healthcare costs. Her research interests include perinatal care, gestational diabetes, hypertensive disorders in pregnancy, and the validation of hospital data to ensure accurate reporting of maternal medical conditions. She also explores fetal surveillance techniques, neonatal jaundice management, and the efficacy of midwifery-led care models. Her work frequently employs mixed-methods and cohort study designs, reflecting a commitment to evidence-based practice. Therese has contributed to studies on uterine rupture, anaemia in pregnancy, and the use of rapid diagnostic tests for preventing neonatal infections. Her articles highlight a focus on healthcare quality, patient-centered care, and improving clinical guidelines through rigorous analysis. The scope of her research spans both clinical and public health dimensions, addressing issues such as antibiotic exposure reduction and maternal morbidity in Australian contexts. Grants: Efficacy and safety of vaccination in at-risk pregnant women and impact on infant immune responses (2017) Are we there yet? Optimising timing of planned birth to improve newborn outcomes and reduce health service costs (2017) Therese is involved in collaborative projects through Sydney Health Partners, focusing on applied research with real-world healthcare implications. Her studies often involve interdisciplinary teams, reflecting her role in bridging clinical practice and academic research. While no formal student advisees are listed, her publications suggest active participation in mentoring research cohorts.

• Obstetrics
• Gynaecology
• Maternal Health
• +5 more

Dr. Kathy Fuller is an Associate Professor of Translational Oncology at The University of Western Australia, serving in the School of Biomedical Sciences within the Pathology and Laboratory Science department. She holds the position of Head of Discipline for Pathology and Laboratory Science and serves as Scientific Lead in the Translational Cancer Pathology Laboratory (TCPL). Dr. Fuller earned her PhD from The University of Western Australia for research into the effects of post-surgical nutrition on gut immunity. Her academic journey includes postdoctoral research at Thrombogenix at Monash University and leadership roles in flow cytometry facilities at UWA, where she developed the Sperm Chromatin Structure Assay (SCSA) for diagnostic use. Her research focuses on developing imaging cytometry protocols for diagnosis and prognosis in haematological malignancies. She investigates megakaryocyte dysregulation in Myeloproliferative Neoplasms and biomarkers for colorectal carcinoma metastasis. Dr. Fuller is particularly known for co-inventing 'immuno-flowFISH,' a patented automated flow cytometry method that detects chromosome signals inside immunophenotyped cells. Her recent publications demonstrate a strong emphasis on applying advanced cytometry to detect chromosomal abnormalities across various leukemias, with multiple 2025 publications showing the ongoing impact of her methodological innovations in cancer diagnostics. Dr. Fuller has received significant recognition including: Australian Museum ANSTO 2018 Eureka Prize for Innovative Use of Technology Queen's Trust for Young Australians Award WA Young Australian of the Year Award (Science and Technology) Raine Medical Research Foundation grant She actively mentors PhD students and has secured substantial funding from NHMRC, Cancer Council WA, Channel 7 Telethon Trust, and Perpetual Philanthropic Services. Her current projects focus on leukemia prevention, novel blood tests for myeloproliferative neoplasms, and improving outcomes for blood cancer patients. Dr. Fuller leads the Translational Cancer Pathology Laboratory where her team develops diagnostic methods with direct clinical applications, particularly in hematological malignancy diagnostics and minimal residual disease detection.

• Flow Cytometry
• Imaging Flow Cytometry
• Hematological Malignancies
• +4 more

Professor Emily Banks is a leading epidemiologist and public health physician at the Australian National University (ANU) College of Health and Medicine, contributing extensively to chronic disease prevention, Indigenous health, and population-level research. Education: MBBS (Honors I), BMedSci (Honors I), PhD Key Roles: Head of the Centre of Epidemiology for Policy and Practice, NHMRC Investigator Fellow, Visiting Professor at Oxford University Her research spans epidemiology , Aboriginal and Torres Strait Islander health , oncology , and cardiovascular medicine , emphasizing large-scale cohort studies to address public health challenges. Recent work explores alcohol-related mortality, Indigenous youth cardiovascular health, and e-cigarette prevention strategies. Over 450 publications highlight her expertise in cohort analysis , cancer risk , and preventive medicine . Awards include the Australian Medical Association Gold Medal and Member of the Order of Australia. Scientific Awards: UK Woman of Achievement in Science (2000) ANU Vice-Chancellor's Awards (2010-2017) National Breast Cancer Foundation Patron’s Award (2014) Order of Australia (2021)

• Epidemiology
• Aboriginal And Torres Strait Islander Health
• Oncology And Carcinogenesis
• +11 more

John Reynolds is an Adjunct Associate Professor (Research) at the Australian Centre for Blood Diseases, within the Faculty of Medicine, Nursing and Health Sciences at Monash University. He is also affiliated with The Alfred Hospital, where he serves as Senior Expert Biostatistician in the Department of Clinical Haematology. His work bridges academic research and clinical practice, focusing on statistical design and analysis in hematology and oncology. Current Affiliation: Monash University & The Alfred Hospital Role: Adjunct Associate Professor (Research), Senior Expert Biostatistician Academic Background: PhD in Statistics with Minor in Genetics, North Carolina State University Prior Experience: Peter MacCallum Cancer Centre, Novartis AG, Deakin University John Reynolds' research is centered on biostatistics in clinical oncology, particularly in hematological malignancies. His primary areas of interest include the design and analysis of clinical trials across all phases, with a strong focus on multiple myeloma, chronic myeloid leukemia, and immune thrombocytopenia. He has contributed significantly to projects involving liquid biopsy, minimal residual disease assessment, and the integration of patient-reported outcomes in clinical decision-making. His early-career work involved statistical design in food and agricultural sciences, showcasing a broad methodological foundation. The recent publications and ongoing projects reveal a consistent trend in applying advanced statistical methods to improve risk stratification, treatment efficacy, and early detection in blood cancers. His work frequently appears in high-impact hematology journals such as Blood , Haematologica , and Blood Advances , reflecting his leadership in biostatistical applications in clinical research. He is actively involved in major research initiatives, including the GLAM study on genomic liquid biopsy in multiple myeloma and trials focused on alcohol use disorders. His contributions are primarily as a Chief Investigator in large collaborative studies, emphasizing his central role in trial design and data interpretation. Invited speaker, American Society of Hematology, Clinical Research Training Institute (2023–2025) Invited speaker, CML Opinion Leader Training (2023) Invited speaker, iCMLf - CML Preceptorship (2019) John Reynolds leads and contributes to numerous federally funded research grants, including projects supported by the Department of Health and Aged Care (Australia). His collaborative network spans institutions in Australia and internationally, with active roles in multi-center clinical trials. He is instrumental in mentoring and advising research teams on statistical rigor, trial design, and data analysis. His lab and team involvement is embedded within the Biostatistics Consulting Platform at Alfred Health and Monash University, where he supports a wide range of clinical research projects.

• Biostatistics
• Oncology Clinical Trials
• Hematology
• +12 more

Stephane Heritier is a Professor (Research) at Monash University's Faculty of Medicine, specializing in Biostatistics, Data Analytics, and Health Economics. He previously held roles at the NHMRC Clinical Trials Centre and The George Institute in Sydney. His expertise includes adaptive trial designs, survival analysis, and robust biostatistics. He is a Chief Investigator on major trials like REMAP-CAP, ITACS, and STAREE-MIND, and leads research funded by NHMRC, ARC, and MRFF grants. He also co-authored the book *Robust Methods in Biostatistics* (2009). Affiliations: Monash University (Primary), University of Sydney (Honorary Associate Professor, 2013–2016) Teaching: Coordinates regression courses in the BCA Master of Statistics and MPH5200 (Epidemiology) Grants & Projects: Includes ARC-funded survival analysis methods (2022–2024), MRFF grants for depression (EMPACT), trauma (FEISTY-II), and ECMO trials (RECOMMEND) Research Interests: Adaptive designs, Bayesian platforms, cluster trials, robust statistics, and translational biostatistics. His work aligns with UN SDGs focused on health and innovation. Advising & Teams: Leads the AusTriM Centre for Clinical Trials Methodology and collaborates on global projects like the DIAAMOND and STAREE-MIND trials. His teams include interdisciplinary experts in medicine, statistics, and healthcare.

• Biostatistics
• Clinical Trial Methodology
• Adaptive Designs
• +5 more

Dr Yvonne Kong is a part-time academic at the Central Clinical School, University of Sydney, where she supports academic and student support programs. She is affiliated with the Haematology Research Group at the Charles Perkins Centre and coordinates Haematology teaching for the Central Clinical School as part of the Sydney Medical Program. Her research focuses on abnormal platelet activation in disease and platelet calcium handling , particularly in the context of thrombosis and myeloproliferative neoplasms. She also contributed to earlier work on wound healing and dermal regeneration through biomaterial applications like tropoelastin. Scientific Awards: Eberhard F. Mammen 2024 Young Investigator Award RCPA Kanematsu Award 2024 Charles Perkins Centre EMCR Travel Funding Award 2024 THANZ Travel Grant recipient 2024 2023 THANZ Scientific Medal Blood 2023 ASH Abstract Achievement Award 2023 THANZ Scientific and Education Trust Research Grant 2023 THANZ Travel/Conference Grant 2023 THANZ Travel Grant recipient 2023 ISTH Early Career Travel Award Dr Kong’s recent publications highlight her expertise in platelet biology (2023) and biomaterial applications in wound healing (2015). Her work bridges haematology, molecular mechanisms of thrombosis, and regenerative medicine.

• Haematology
• Platelet Biology
• Calcium Signaling
• +3 more

Professor Denise Jackson is a faculty member in the Department of Health and Biomedical Sciences at RMIT University, Bundoora West campus. She serves as the Head of the Thrombosis and Vascular Biology laboratory and holds an honorary fellowship from the National Health and Medical Research Council (NHMRC). Her research focuses on thrombosis mechanisms, platelet biology, and immunoreceptor roles in infection and immunity. She coordinates courses such as MEDS1142 Medical Informatics, BUSM3220 Medical Laboratory Quality Systems, and ONPS2153 Medical Informatics and Laboratory Management. Research Interests: Professor Jackson’s work spans thrombosis, platelet function, mouse models of thrombus formation, and the molecular mechanisms of immunoreceptors in pathogens. Her team investigates tetraspanins’ role in blood clot regulation and signaling pathways in platelets. Key projects include studying tyrosine kinase inhibitors’ effects on haemostasis and exploring immunoreceptor crystal structures for drug design. Professional Involvement: She reviews grants for NHMRC, National Heart Foundation, and international bodies like the Wellcome Trust and NSF. She also serves as a reviewer for journals including Nature and Blood . Student Supervision: Principal supervisor of 12 Honours, 3 Masters, and 4 PhD students. Labs/Teams: Leads the Thrombosis and Vascular Biology lab, collaborating on drug development and thrombosis prevention strategies.

• Thrombosis
• Haematology
• Cardiovascular Medicine
• +5 more

Hannah Newnes is a Research Associate at the School of Biomedical Sciences, The University of Western Australia. Her work focuses on immunology and cancer research, particularly the role of type I interferons in antitumor immunity and immunotherapy. She is affiliated with the University of Western Australia (M503) and holds an ORCID ID (0000-0003-1647-975X). Current position: Research Associate Institution: The University of Western Australia Research focus: Immunotherapy, Tumor Microenvironment, Interferon Signaling Research Interests: Hannah's research explores how type I interferons modulate immune responses in cancer contexts. Key areas include: Differential activation of immune cells (T cells, NK cells) via interferon subtypes Mechanisms linking burn injury to cancer incidence Overcoming therapeutic resistance in tumor microenvironments Immunomodulatory cytokines (e.g., interleukin-4) in cancer treatment Systems-level understanding of immune-cancer interactions Translational immunotherapy for solid cancers Research Output Trends: Her publications (9 total) span 2021–2025, with recent emphasis on type I interferon subtypes, T cell activation, and tumor microenvironment in high-impact journals like Science Advances and Cancers . Collaborative work with teams across immunology, oncology, and biomedical sciences dominates her output. Grants: She contributed to a Cancer Council WA-funded project (2024–2025) titled Enhancing T cell-based immunotherapies for solid cancers . Contact: Email: hannah.newnes@uwa.edu.au

• Immunology
• Cancer Research
• Tumor Microenvironment
• +3 more

Professor Ian Kerridge is a renowned academic at the University of Sydney , where he holds the Chair in Bioethics and Medicine at Sydney Health Ethics (SHE) . He is also a Staff Haematologist/Bone Marrow Transplant physician at Royal North Shore Hospital in Sydney. His career spans clinical practice, academic leadership, and interdisciplinary research, with a focus on bridging philosophical inquiry and empirical bioethics in healthcare. Education: Trained in medicine at the University of Newcastle, bone marrow transplantation (BMT) at the Royal Free Hospital in London, and philosophy at the Universities of Sydney, Newcastle, and Cambridge. Research Interests include biomedical ethics, public health ethics, organ transplantation, stem cell research, end-of-life care, and the socio-cultural implications of medical innovation. He has extensively explored conflicts of interest, over-diagnosis, and the commercialization of healthcare, particularly in reproductive medicine and transplantation. Teaching & Supervision : Coordinated the Masters in Bioethics program at the University of Sydney and supervises students across medicine, philosophy, nursing, and humanities in Honours, Masters, and Doctoral projects. Leadership Roles: Former Director of SHE (2003-2015) and the Clinical Unit in Ethics and Health Law at the University of Newcastle (1995-2001). Committee Memberships: Chair of the South East Sydney LHD Clinical Ethics Committee, member of the Australian Ethical Health Alliance (AEHA), NSW Health Ethics Advisory Panel, and Director of Praxis Australia. Publications : Authored 6 textbooks and over 500 peer-reviewed papers, with recent work examining the ethical implications of health data use, pandemic research integrity, and the cultural dimensions of assisted dying.

• Biomedical Ethics
• Global Health
• Haematology
• +4 more